Fig. 5.

KLF1 activation enhances iPSC-derived erythroid cell production. a Total cell number of iPSC-derived erythroid cells cultured alone or in co-culture with iKLF1.2-DMs in the presence and absence of tamoxifen (Tam) from day 18–28 of differentiation (n = 4 biologically independent samples, one-way ANOVA with Tukey’s post-test). b Viability of iPSC-derived erythroid cells at day 28 following above culture conditions (n = 4 biologically independent samples, one-way ANOVA with Tukey’s post-test). c Live CD235a⁺-gated iPSC-derived erythroid cells that are negative for CD71 and Hoechst staining following above culture conditions (n = 4 biologically independent samples; one-way ANOVA with Tukey’s post-test). d Quantification and statistical analysis of the absolute number of mature, enucleated erythroid cells in replicate experiments as described above (n = 4 biologically independent samples; one-way ANOVA with Tukey’s post-test). e Fold change of mature, enucleated iPSC-derived erythroid cells following co-culture with iKLF1.2-DMs (−/ +tamoxifen) compared to iPSC-derived erythroid cells cultured alone (− tamoxifen) (n = 4 biologically independent samples; one-way ANOVA with Tukey’s post-test). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001